Pharmaceuticals

Zydus Lifesciences / Dr. Reddy’s

in focus after U.S. FDA issued an EIR (inspection report) related to an Ahmedabad oncology unit — pharma stocks moved on regulatory update news; Dr Reddy’s showed resilient month-on-month performance. Why it matters: Regulatory actions (FDA inspections, EIRs) can delay product approvals or shipments to the U.S. and affect revenues — markets react immediately. Beginner takeaway: For pharma stocks, regulatory risk is as important as sales growth — a product approval or a compliance issue can swing valuations. Suggested action: Read company regulatory updates and USFDA status notes before reacting — a temporary sell-off can be an entry point if fundamentals remain strong.